

**IN THE UNITED STATES PATENT OFFICE**

Patent Application Serial No.: 10/800,741

Our Ref: PT-2091001

**CUSTOMER NO. 23607**

Applicants: Aptoex Pharmachem Inc.

Agent: Ivor M. Hughes  
Barrister & Solicitor  
Patent & Trade Mark Agents  
Suite 200.  
175 Commerce Valley Dr. W.  
Thornhill, Ontario.  
L3T 7P6, CANADA

Title: AN IMPROVED PREPARATION OF ATORVASTATIN

Group Art Unit: 1614

No. of Pages including this sheet: 4

**DELIVERED TO FACSIMILE NO. (703) 746-9195**

June 23, 2004


Commissioner of Patents  
U.S. Patent and Trademark Office  
220 20<sup>th</sup> Street S.  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202**Attention: Office of Initial Patent Examination's Filing Receipt Corrections**

Dear Sir:

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper:

- 1) Letter dated June 23, 2004 outlining corrections to Filing Receipt
- 2) Copy of Filing Receipt with corrections.

is being facsimile transmitted to the United States Patent Office Facsimile  
No. (703) 746-9195 on the date shown below.MARCELO K. SARKIS  
Agent for ApplicantSignature: 

Date: June 23, 2004



# Ivor M. Hughes

*Barrister & Solicitor*

*Patent & Trade Mark Agents  
Canada, United States*

**Barristers & Solicitors**

*Ivor M. Hughes*

*Rick Tuzi*

*Mark Ng*

**Patent Agents**

*Neil H. Hughes, P.Eng.*

*Marcelo K. Sarkis, P.Eng.*

*Wm. Kitt Sinden*

Our Ref: PT-2091001

June 23, 2004

**VIA FACSIMILE**

The Commissioner of Patents  
UNITED STATES PATENT OFFICE  
220 20<sup>th</sup> Street S.  
Crystal Plaza 2, Lobby, Room 1B03  
Arlington, Virginia 22202

**Attention: Office of Initial Patent Examinations Filing Receipt Corrections**

Dear Sirs:


**Re: United States Patent Application No. 10/800,741  
of Apotex Pharmachem Inc. (formerly known as Brantford Chemicals Inc.)  
for AN IMPROVED PREPARATION OF ATORVASTATIN  
Filing Date: March 16, 2004  
Group Art Unit: 1614  
Customer No. 23607**

Pleased be advised that we found errors in the filing receipt which we received in respect of the above-identified Application. In the filing receipt, a copy of which we are enclosing for your reference, Canadian Patent Application No. 2,460,935 filed on March 15, 2004 should be added under Foreign Applications. The name of the Applicant, Brantford Chemicals Inc. has been changed to Apotex Pharmachem Inc. Applicant's Agent filed a change of name document with USPTO on May 5, 2004. Also the title of the invention is incorrect. The title should read as follows "AN IMPROVED PREPARATION OF ATORVASTATIN". The words "an improved" were omitted from the title of the invention.

We kindly ask that the filing receipt be corrected to reflect the foreign application of Canadian Patent Application No. 2,460,935, the Applicant's name of Apotex Pharmachem Inc. and correct title of invention.

We thank the Commissioner for his co-operation in this regard, and look forward to receiving the corrected filing data in this matter.

Respectfully submitted,



Marcelo K. Sarkis  
Registration No. 37,015  
Agent for the Applicant

MKS/lvp  
Enclosure



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov


| APPL NO.   | FILING OR 371<br>(a) DATE | ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|---------------------------|----------|---------------|-----------------|----------|----------|----------|
| 10/800,741 | 03/16/2004                | 1614     | 1430          | PT2091001       |          | 22       | 5        |

CONFIRMATION NO. 1163

23607

IVOR M. HUGHES, BARRISTER & SOLICITOR,  
PATENT & TRADEMARK AGENTS  
175 COMMERCE VALLEY DRIVE WEST  
SUITE 200  
THORNHILL, ON L3T 7P6  
CANADA

## FILING RECEIPT



0000000012820389\*

Date Mailed: 06/01/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-748-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Bhaskar Reddy Guntoori, Brantford, CANADA;  
Daqing Che, Brantford, CANADA;  
Fan Wang, Hamilton, CANADA;  
Yajun Zhao, Brantford, CANADA;  
K.S. Keshava Murthy, Ancaster, CANADA;  
Stephen E. Horne, Burlington, CANADA;

## Assignment For Published Patent Application

~~Brantford Chemicals Inc.;~~ Apotex Pharmachem Inc.

## Domestic Priority data as claimed by applicant

## Foreign Applications

Canada 2,460,935 03/15/2004

If Required, Foreign Filing License Granted: 05/28/2004

Projected Publication Date: 09/22/2005

Non-Publication Request: No

Early Publication Request: No

**Title**

An Improved Preparation of atorvastatin

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).